wall street dow jones

ESports are making a name, and a market for themselves, and SPYR, INC (OTCQB:SPYR), is making a strategic play to capture its share of the growing industry.

The Denver based holding company that through its wholly owned subsidiary SPYR APPS, LLC, develops and publishes mobile application and eSports, recently announced plans to spin off company’s restaurant division, Eat at Joe’s庐 as a separate publicly traded company. SPYR, INC (OTCQB:SPYR) announced that it will give all of its shareholders of record as of May 19, 2017, a dividend in the form of shares in what is to become a new and separate publicly traded company. SPYR will issue each of its shareholders an equal number of shares (1 for 1) in a new spin-off company, which SPYR is creating in order to divest itself from its restaurant division.

wall street dow jones: SolarWindow Technologies, Inc. (WNDW)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    SolarWindow Technologies, Inc. (OTCQB:WNDW) is another third-party currently engaged in research and development to incorporate one of GLW’s glass products in an innovative manner. WNDW, a leading developer of transparent electricity-generating coatings for glass windows and flexible veneers, announced its plan to develop electricity-generating flexible glass. In particular, WNDW’s scientists and engineers recently applied layers of its liquid coatings onto GLW’s Willow Glass and laminated them under conditions that simulate the high pressure and temperatures of the manufacturing processes used by commercial glass and window producers. The result was a bendable glass “veneer” which generates electricity. WNDW anticipates installing these sheets of electricity-generating glass veneers over existing office tower windows, turning buildings into vertical power generators and helping decrease their carbon footprint. The company also believes that such veneers could be applied to flat and curved surfaces on automobiles, trucks, buses, airplanes, and boats to generate onboard electrical power. WNDW’s veneer products are being developed in collaboration with the U.S. Department of Energy’s National Renewable Energy Laboratory in an effort to commercialize WNDW’s products. While we saw no specific timeline for when WNDW would offer its products incorporating Willow Glass, we are once again excited by this innovative use of a GLW product.

wall street dow jones: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) jumped as much as 14.5% today after announcing earnings after the bell yesterday. As a development-stage biotech, it wasn’t the revenue or the earnings that caused the spike, but the progression of Allnylam’s pipeline.

  • [By Ben Levisohn]

    Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in its favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.

  • [By Lisa Levin]

    Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares shot up 53 percent to $114.87 after the company impressed investors with encouraging data from a phase 3 clinical trial. Alnylam, a company dedicated towards treating a wide range of debilitating diseases through ribonucleic acid (RNA) interference (RNAi) therapeutics, said after Tuesday's market close that a phase 3 study called APOLLO met its primary efficacy endpoint and all secondary endpoints.

  • [By Chris Dier-Scalise]

    On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the time of the downgrade was edging positive, with 66 percent of Vetr user rating bullish.

  • [By Cory Renauer]

    Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS), saw a mix of setbacks and success in 2016.

wall street dow jones: Applied Materials, Inc.(AMAT)

Advisors’ Opinion:

  • [By Craig Jones]

    On CNBC's "Fast Money Halftime Report", Pete Najarian spoke about a bullish options activity in Applied Materials, Inc. (NASDAQ: AMAT). He noticed that somebody sold 12,000 contracts of the September 42 puts in the first half of the trading session on Tuesday. Najarian explained that the trader believes that the pull back might be over and the stock is close to the bottom.

  • [By Chris Neiger]

    Applied Materials (NASDAQ:AMAT) made investors very happy last year as the company’s stock price rose more than 74%. And that growth has continued into this year, with Applied Materials up more than 10% since the beginning of 2017.

  • [By Elizabeth Balboa]

    NVIDIA Corporation (NASDAQ: NVDA), Amazon.com, Inc. (NASDAQ: AMZN), Applied Materials, Inc. (NASDAQ: AMAT) and Micron Technology, Inc. (NASDAQ: MU) — “annihilated.”

  • [By William Patalon III]

    Shares of chip-equipment leader Applied Materials Inc. (Nasdaq: AMAT) have zoomed 80% since we brought them to you in May 2014.

    And they’ve jumped 8% since we re-recommended the stock back on Jan. 31.

  • [By Chris Lange]

    Short interest in Applied Materials Inc. (NASDAQ: AMAT) rose to 13.95 million shares. The previous reading was 13.21 million. Shares were trading at $38.55, in a 52-week range of $19.46 to $39.81.

  • [By ]

    As the term implies, a 15% trailing stop-loss “trails” the price of the stock. So as the price moves up, so should your stop-loss. Let’s look at Applied Materials (Nasdaq: AMAT) as an example. On September 29, 2017, the stock closed at a new high of $52.09. That means the 15% trailing stop-loss would have been $44.28 (52.09 x .15 = 7.81; 52.09 – 7.81 = 44.28). Had the stock gone on to close below $44.28 we would have sold the next trading day.

wall street dow jones: Methanex Corporation(MEOH)

Advisors’ Opinion:

  • [By Jim Robertson]

    Back in February of last year, we suggested Methanex Corporation (MEOH), which ended up providing us with some pretty good gains in a fairly short amount of time, and based on what’s happening with the stock technically right now, it could be another gainer over the next several days to few weeks.

wall street dow jones: RXI Pharmaceuticals Corporation(RXII)

Advisors’ Opinion:

  • [By Jim Robertson]

    Yesterday, our Under the Radar Moversnewsletter suggested small cap clinical-stage biotech RXi Pharmaceuticals Corp (NASDAQ: RXII) as a long/bullish trade for our short-term portfolio:

Leave a Reply

Your email address will not be published. Required fields are marked *